Literature DB >> 3146861

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

J Beck1, P Rondot, L Catinot, E Falcoff, H Kirchner, J Wietzerbin.   

Abstract

We have carried out a longitudinal study of interferon (IFN) and tumor necrosis factor (TNF) using a whole-blood mitogen stimulation assay in 20 multiple sclerosis (MS) patients and in a healthy control group. We set up individual profiles and the results were quite constant for each individual, both in healthy donors and in the patients in remission. Before exacerbations, however, we found an increase of IFN-gamma and TNF production preceding clinical symptoms by a maximum of 2 weeks. In benign cases, the increase disappeared rapidly, even before the appearance of symptoms, whereas we found sequelae whenever the increase persisted during weeks. In chronic progressive patients, we frequently found intervening increases. It may be that IFN-gamma and TNF trigger off exacerbations at a very early stage and that these cytokines may also play a role in maintaining disease in chronic progressive and invalidating forms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146861     DOI: 10.1111/j.1600-0404.1988.tb03663.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  79 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.

Authors:  M Dettke; P Scheidt; H Prange; H Kirchner
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

4.  Different profile of cytokine synthesis according to the severity of acute pancreatitis.

Authors:  Raquel Laveda; Juan Martinez; Carlos Munoz; Juan-Carlos Penalva; Jesus Saez; German Belda; Salvador Navarro; Faust Feu; Anton Mas; Jose-Ma Palazon; Jose Sanchez-Paya; Jose Such; Miguel Perez-Mateo
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

5.  Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.

Authors:  Esther Shohami; Raphael Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

6.  [Noninflammatory pathogenesis of lesions in multiple sclerosis].

Authors:  M E Kornhuber
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

7.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

8.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

10.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.